Blood cancers

Oral azacitidine maintenance therapy improves OS in AML

An oral formulation of azacitidine has been shown to improve overall and relapse free survival in patients with AML in their first remission after intensive chemotherapy. Associate Professor Andrew Wei, head of leukaemia research at The Alfred, told the ASH 2019 meeting in Orlando that the drug known as CC-486 was the first maintenance therapy ...

Already a member?

Login to keep reading.

© 2021 the limbic